Changeflow GovPing Healthcare & Life Sciences Investigating the Prevalence and Risk Factors f...
Routine Notice Added Final

Investigating the Prevalence and Risk Factors for Sarcopenia amongst Adults Seeking Treatment for Obesity

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH ClinicalTrials.gov registered NCT07541677, an observational study investigating the prevalence and risk factors for sarcopenia among 300 adults seeking treatment for obesity at a specialized Obesity Center. The study will explore demographic, lifestyle, and clinical factors including age, gender, race, BMI, smoking, alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Investigators expect higher sarcopenia prevalence among Asian participants due to differences in body composition.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NCT07541677 is a newly registered observational study on ClinicalTrials.gov describing a clinical investigation into sarcopenia prevalence and risk factors among 300 adults with obesity. The study is classified as observational and will enroll participants at a specialized Obesity Center, examining factors such as age, gender, BMI, smoking, alcohol use, physical activity, and dietary protein intake.

Affected parties include clinical researchers, obesity treatment centers, and public health authorities with an interest in muscle-mass disorders. The study findings may inform future screening practices for sarcopenia in obesity care settings; however, this registry entry does not create any compliance obligations or reporting requirements. It is an informational record of a planned clinical investigation.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity

Observational NCT07541677 Kind: OBSERVATIONAL Apr 21, 2026

Abstract

Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%.

In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups.

The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments.

Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By dete...

Conditions: Obesity

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
NCT07541677

Who this affects

Applies to
Healthcare providers
Industry sector
6221 Hospitals & Health Systems
Activity scope
Clinical research Observational study
Threshold
300 adults with obesity
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!